Amazing how the NASDAQ listing was an opportunity to liberate this company from the obtuseness of the Australian Biotech investor population.
From the trading volumes on the NASDAQ it appears the US Biotech crowd have little interest in MESO, some may even say it is illquid. If we are back to the ASX leading the way, then there is only one way and that is down, unfortunately.
-
- There are more pages in this discussion • 45 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.74 |
Change
0.015(0.87%) |
Mkt cap ! $2.220B | |||
| Open | High | Low | Value | Volume |
| $1.73 | $1.76 | $1.70 | $2.149M | 1.244M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 15 | 26695 | $1.74 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.74 | 80729 | 12 |
View Market Depth
| Last trade - 11.55am 17/07/2025 (20 minute delay) ? |
| MSB (ASX) Chart |